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Cancer Core Europe is a European legal alliance consisting of seven lead-
ing cancer centres – most of them Comprehensive Cancer Centres (CCCs)
– with a single portal system to engage in various research projects with
partners. Cancer Core Europe was established to create a sustainable,
high-level, shared research infrastructure platform hosting research collabo-
rations and task forces (data sharing, clinical trials, genomics, immunother-
apy, imaging, education and training, and legal and ethical issues), with a
controlled expansion agenda. Translational cancer research covers the can-
cer research continuum from basic to preclinical to early clinical, late clini-
cal, and outcomes research. Basic–preclinical research serves as the ‘engine’
for early clinical research by bridging the early translational research gap
and is the primary and current focus of the consortium as exemplified by
the launching of the Basket of Baskets trial, Europe’s largest precision can-
cer medicine trial. Inspired by the creation of Cancer Core Europe, the pre-
vention community established Cancer Prevention Europe, a consortium of
ten cancer prevention centres aimed at supporting the complete prevention
research continuum. Presently, Cancer Core Europe and Cancer Prevention
Europe are integrating therapeutics and prevention strategies to address in
partnership the widening cancer problem. By providing innovative
approaches for cancer research, links to healthcare systems, development
of quality-assured multidisciplinary cancer care, and assessment of long-
term outcomes, the virtual infrastructure will serve as a hub to connect
and interact with other centres across Europe and beyond. Together, Can-
cer Core Europe and Cancer Prevention Europe are prepared to function
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as a central engine to tackle, in collaboration with various partners, a
potential ‘mission on cancer’ addressing the cancer burden.
1. An alarming increase of the cancer
problem in Europe and the World
Europe is facing a significant burden in connection with
cancers. While representing less than 10% of the global
population, our continent is dealing with a quarter of
all cancers. Moreover, these numbers are expected to
increase due to our ageing societies. It is estimated that
over 3.9 million Europeans will be diagnosed with can-
cers in 2018 and that almost 2 million in the same year
will die from these diseases. A majority of cancer
patients (55%) will gain a prolonged disease-free sur-
vival, and cure, but big killers with a relatively low
impact of treatment remain, such as lung cancer (20%
of all cancer deaths), colorectal cancer, advanced breast
cancer, and pancreatic cancer (Ferlay et al., 2018).
These numbers are hiding important differences,
observable in terms of incidence, stage at diagnosis,
treatment opportunities, access to innovation of sys-
temic treatments, and healthcare coverage, both at the
country level (a divide between northern and western
Europe and southern, central and eastern Europe) and
at the regional level within a given country. Though the
mortality rates decrease in the occidental part, they
remain high in the more oriental regions of Europe.
Similar data show that low-income countries in the
world are facing what looks like epidemics of cancers
caused by the epidemiological transition (Corbett et al.,
2018). In Europe, a 10% (around 20% according to the
CPE manifest) increase in cancer incidence is expected
in the next 15 years. As many as 13 million patients will
be considered long-term survivors in 2035, in need of
professional and social support and demanding contin-
uous research efforts in order to reduce long-term side
effects of treatments, to avoid secondary cancers and to
facilitate full reintegration into society in all aspects.
2. The increasing economic burden of
cancer
The indirect cost of cancer due to premature death and
disability (i.e. excluding the medical expenses) is grow-
ing worldwide, being estimated at almost 900 billion
USD in 2008 (Sullivan et al., 2011). However, no clear
relationship between these high costs and the increasing
incidence and mortality data has been established. In
the EU countries, the economic burden was calculated
at €126 billion in 2009, €52 billion in productivity loss,
€37 billion on health care and €13 billion on drug
expenses. Spending on cancer drugs has increased from
€7.6 billion in 2005 to €19.1 billion in 2014 due to an
increased number of patients treated better, but at very
high costs (J€onsson et al., 2016; Luengo-Fernandez
et al., 2013). Moreover, there is a huge variation in the
availability of drugs within different EU countries as
well as a significant variation in their costs (Cherny
et al., 2016). Comprehensive approaches to the various
cancer diseases and their related expenses are therefore
required in all fields, from cancer prevention to preci-
sion care, from basic research to clinical trials and
cohort surveys, including the support from mathemat-
ics, informatics and social sciences. The patient contri-
bution to research, treatment decisions and healthcare
policies, individually and collectively through their rep-
resentatives, is also mandatory to change the vision of
cancer prevention and cure.
3. A cancer research continuum
Traditionally, progression from basic research to
patient’s treatment with new therapeutics is a long and
fragmented road, with ad hoc bridges being required
between each separated step. The process is not efficient
regarding energy, interaction between research and the
health care, patient involvement, and time or money,
and a result, a universal paradigm shift is needed to
challenge cancer effectively. Cancer research must
develop new therapeutic approaches and also design
fast, reactive and efficient clinical trials that spare the
patients’ contributions, and the only way to do this effi-
ciently is by streamlining the process. Creating a con-
tinuum that covers basic, preclinical, early and late
clinical and outcomes research depends on having a
common agenda and a willingness to share quality-con-
trolled data. Information and data generated in every
phase must be accessible to speed up the knowledge
process and prevent stalling. This concept is fulfilled by
collaborations between CCCs, patient-focused entities
capable of undertaking every stage of the process.
4. Creating research infrastructures in
Europe over time
There is a need to consolidate and focus the frag-
mented European research towards innovation within
the fields of prevention and therapeutics, in order to
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address the healthcare, social and economic challenges
of cancer. In 2006, a pivotal FP6 project, EURO-
CAN+Plus, provided the first step in the process
towards a larger, more consistent effort to fight cancer,
and at its conclusion in 2008, several key findings and
‘next steps’ were proposed. A paradigm shift was
deemed necessary to eliminate the segmented process
of cancer research with little interaction between each
step of the research continuum, and the development
of CCCs, institutions that link research with the
healthcare system, was emphasized. Furthermore, it
was concluded that there was a need for creating a
uniform platform for translational cancer research to
bring together enough centres to generate the critical
mass of patients, expertise and resource required to
make a significant breakthrough in cancer care.
Building on these suggestions, the FP7 EurocanPlat-
form network of excellence was launched in 2011,
emphasizing the need to stimulate multisite transla-
tional cancer research policies. A direct outcome of
this project was the formation of Cancer Core Europe
in 2014, with the sole objective of developing a sus-
tainable infrastructure for the next era of translational
cancer research. Cancer Core Europe is now a legal
entity including seven European large cancer centres,
most of which are CCCs.
Inspired by the creation of Cancer Core Europe, the
leaders of 10 research institutes with prominent cancer
prevention programmes in Europe (IARC in France,
and institutes in the UK, DK, NL, Germany, Sweden
and Italy) recently established Cancer Prevention Eur-
ope (CPE) (Forman et al., 2018). CPE is a consortium
of multidisciplinary centres focused on reducing cancer
mortality and morbidity through development of pre-
vention policies and early diagnostic techniques (For-
man et al., 2018, article in the same issue). A
partnership between Cancer Core Europe and CPE
would encompass every facet required to tackle the
cancer challenge at an unprecedented level. It would
structure a European hub able to support and drive
innovation in every sector, linking healthcare systems
together, and ensuring alignment of policies towards
prevention and translational research.
5. The Cancer Core Europe initiative
(a) Bottom-up initiative: Following the suggestion that
a bottom-up initiative would be required to make
these changes at the European level, Alexander
Eggermont (Gustave Roussy Cancer Campus
Grand Paris) and Otmar Wiestler (DKFZ-NCT,
the German Center for Cancer Research and the
National Center for Tumor Diseases, Heidelberg)
spearheaded the creation of Cancer Core Europe
in 2014 (Eggermont et al., 2014). By linking centres
with robust basic/preclinical research with those
having an outstanding experience in early phase
clinical trials, it would be possible to set the
agenda for addressing the translational research
continuum, and to provide further care implemen-
tation and outcomes research focused on the inno-
vative therapeutic needs required for balancing the
growing cancer problem. The consortium now
includes the Gustave Roussy Cancer Campus
Grand Paris; Cambridge Cancer Centre, Cam-
bridge; the Netherlands Cancer Institute, Amster-
dam; Karolinska Institutet, Stockholm; the Vall
d’Hebron Institute of Oncology, Barcelona; the
German Center for Cancer Research and the
National Center for Tumor Diseases, Heidelberg;
and the Istituto Nazionale dei Tumori, Milano
(Calvo et al., 2018).
(b) Sharing infrastructures and sharing data: Cancer
Core Europe is a shared research infrastructure
with research collaborations and task forces (com-
mon research data sharing expanded to the
patient’s care pathway observation and outcomes;
innovative clinical trials associating large numbers
of patients for fast results; shared genomic plat-
form with common bioinformatics tools to provide
usable molecular results and help medical tumour
boards; imaging and radiomics; training and edu-
cation, legal and ethical issues, and coordination
across borders) that have representatives from all
participating centres. The consortium is in the pro-
cess of moving towards a virtual single ‘e-hospital’
with shared translational research activities and
compiled databases. Common clinical molecular
profiling, initially developed in some centres, is
now shared by all institutes and linked to a data
centre, which enables computational biology to
provide validated diagnostic information; in addi-
tion, standard operating procedures are currently
under development for tissue and liquid biopsies
along with ‘omics’ technologies, single-cell analy-
ses, functional genetics, immune profiling,
proteomics, etc.
(c) The basket of baskets trial (BOB): Clinical and
translational research with a focus on innovative
precision cancer medicine handles a large number
of specific subgroups of tumours characterized by
individual molecular characteristics, and thus offers
new possibilities to stratify patients for treatment.
Given the large number of patient subgroups, tra-
ditional clinical trials methodology must move
towards next-generation clinical trials, and an
3Molecular Oncology (2019) ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
A.M.M. Eggermont et al. Cancer Core Europe
integrated clinical trials structure is currently being
used for a major precision cancer medicine initia-
tive, known as ‘the Basket of Baskets trial’ (BOB;
see Fig. 1). In brief, patients with refractory disease
are screened for their genomic abnormalities using
a 350-gene panel on their initial tumour, followed
up with ctDNA, and according to the results,
directed to receive an appropriate treatment under
different modules (defined by class of mutation-dri-
ven signalling pathways, epigenetic modulations,
hypermutated tumours, etc.) following the decision
of the medical tumour board, with drugs being
provided by pharma companies. When a recent
biopsy is available, tumours are sequenced at mul-
tiple sites (whole-genome sequencing and RNAseq
in one platform) providing additional elements to
the treatment decision, and discovery of new
biomarkers. Inside a module addressing a particu-
lar gene pathway, there may be stratification
according to different molecular alteration types.
The biostatistics survey allows all these subgroups
a limited number of inclusions which can be
expanded if a response signal is observed. Addi-
tional modules can be implemented as amendments
during the master protocol evolution, making it
flexible and reactive. This protocol is, therefore, a
long-term, adaptable and expandable clinical trial,
histology agnostic, allowing the development of
biomarkers. All steps are under the expertise of a
task force with quality control.
(d) Standardizing and developing radiomics: The added
value of modern functional and molecular imaging
technologies and image analysis (radiomics) is
another area of attention for the consortium; to
analyse heterogeneity of metastatic disease and
predict response to therapy, data must be shared
following image harmonization between centres.
Common clinical databases permit assessments of
clinical effectiveness and outcomes on a longitudi-
nal term based on health-economics studies.
Finally, educational activities are also considered
to be essential: Cancer Core Europe is organizing
an annual Summer School for Translational Can-
cer Research, offering a full-week immersion of
PhDs and MDs with experts from all over Europe
to help them exchange ideas and projects. This
school is open to all European students to train
the next generation of leaders of translational and
clinical oncology all over our continent and
beyond. Further information is provided on the
website: https://www.cancercoreeurope.eu/edu
cation-and-training/; see also article by I. Ernberg
in this issue.
(e) Patient participation: The role of the patients them-
selves in the process is also of key importance since
they are the start as well as the end point. The
European Cancer Patient Coalition (ECPC) is
working with the Cancer Core Europe Board of
Directors to develop the best synergistic relation-
ship with patients, with the objectives of informa-
tion, complete awareness and participation in
research projects, in treatment decision, follow-up
of care and outcomes, and therefore contributing
to patient empowerment.
(f) A legal entity with critical mass and single portal:
Cancer Core Europe is a consortium with a legal
entity (alliance) which will support open science
and sharing of resources. It has a rotating leader-
ship; at present, Eggermont from Gustave Roussy
is the chairman and Calvo the Chief Scientific Offi-
cer. The critical mass is substantial, with around
60 000 newly diagnosed patients, about 300 000
treated patients and approximately 1 200 000 con-
sultations annually. Furthermore, over 1500 clinical
trials are being conducted at the consortium. Can-
cer Core Europe will expand in the future, and the
Fig. 1. The Basket of Baskets Clinical Trial process. (A)
iPROFILER: a 2-tier process of increasing resolution to identify
potential candidate and determine their molecular signature. (B)
iBASKET: the array of modules in the trial process, each of which
focuses on a different pathway. Within each module, there are
several arms that target specific components of the modules
pathway. (C) The outcomes of BOB.
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inclusion of new participants will be based on sci-
entific excellence and the need for additional speci-
fic research geometries.
(g) Designation of excellence programme: The Euro-
pean Academy of Cancer Sciences has a quality
assurance programme for translational cancer
research designating CCCs of Excellence (Ring-
borg et al., 2018). In an ongoing process, the Can-
cer Core Europe participants use this process to
quality-assure translational research, and new par-
ticipants are expected to use the same assessment
procedure. In addition, each centre has the mission
to work in its own country setting up collabora-
tion with other CCCs.
6. Collaboration and expansion for
future perspectives in Europe and
beyond
Collaboration between centres working at any level of
the continuum is paramount for rapid advancement in
tackling the challenges posed by cancer in all coun-
tries. The infrastructure created by Cancer Core Eur-
ope accelerates the research continuum and has
designed a launching pad for advancing personalized
and precision medicine. To further expand and share
this infrastructure with all EU countries (and poten-
tially beyond), Cancer Core Europe will grow by
including additional centres at two levels. One central
member will be identified per country to form the core
network of Cancer Core Europe.
6.1. Expansion plan and initiation of associated
members and networks
The expansion plan by Core Centres will be performed
at a controlled rate because centres need time to pre-
pare for membership with respect to structural, legal
and collaborative requirements. The second expansion
level is per country, identifying associated members for
participation in translational research networks with
the core institutes. Examples could be the DKTK net-
work in Germany (see a separate chapter in this vol-
ume), the SIRIC centres network in France, the
personalized cancer medicine network in the Nether-
lands, and the Comprehensive Cancer Centres network
in Catalonia. Ultimately a rapidly increasing super-
structure will emerge with supracritical mass to
address outcomes research programmes in Europe and
to create databases facilitating patient care and treat-
ment through artificial intelligence-driven discoveries
(Lawler et al., 2018). Cancer Core Europe will
collaborate with national and international research
networks to increasingly cover all relevant research
areas. CCCs will be pivotal for accelerating the devel-
opment of potential clinical innovations. There must
be at least one in every EU nation, and they must be
more closely tied to the existing clinical research net-
works, improving the evaluation of the benefits for
patients and the healthcare system in the later stages
of the continuum.
6.2. Programmes to expend east and southeast
wards
In order to accelerate construction of a bridge with
centres in Eastern Europe, Cancer Core Europe mem-
bers will each build one-on-one developmental pro-
grammes with designated centres to address their
needs and to accompany them through bilateral educa-
tion and training programmes and infrastructure build-
ing programmes to accelerate their development
towards Cancer Core Europe membership.
6.3. Transfer of expertise
Cancer Core Europe also represents a vast wealth of
transferable expertise. Any centre joining will have
access to all Cancer Core Europe activities, which will,
in turn, expand the individual centres’ competences.
Centres currently without the scope to run trials will
be able to do so through the clinical trials platform,
and the close connection to all levels of the transla-
tional research continuum will benefit and expand on
the potential of cancer research as a whole. In essence,
a borderless translational research entity will be
formed, providing the critical mass of expertise,
patients and utilities, also allowing for the expansion
of activities to include the advancement of diagnostics,
prevention, healthcare policies, socio-economic ramifi-
cations, patient rights and survivorship care.
7. A mission on cancer will provide
new hope
In 2017, a mission on cancer was proposed, stating that
‘by combining innovative prevention and treatment
strategies in a sustainable state-of-the-art virtual Euro-
pean cancer centre/infrastructure, it will be possible by
2030 to achieve long-term survival in three out of four
cancer patients in countries with well-developed health-
care systems. Furthermore, the concerted actions will
pave the way to handling the economic and social
inequalities in countries with less-developed systems’
(Celis and Pavalkis, 2017). In June 2018, a press release
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from the European Commission concerning Horizon
Europe stated that ‘Examples of missions could range
from the fight against cancer, to clean transport or plas-
tic-free oceans. Missions will be codesigned with citi-
zens, stakeholders, the European Parliament and the
Member States’ (EU Press release, 2018). The initiation
of a mission on cancer directed towards all aspects of
cancer health care (the research continuum, prevention,
health economics, social impact, patient well-being and
rights, infrastructure development such as CCCs, etc.) is
the most viable option to instigate real change in the
field and to demonstrate the social impact of research.
8. Future perspectives: How do we get
there?
Clearly a lot of work needs to be done to have a success-
ful integration of the different components of a mission
on cancer. Such an integration will need collaborations
with a variety of networks. The uniqueness of Cancer
Core Europe makes it the ideal ‘engine’ for a mission on
Cancer. The bottom-up approach, the fusion of basic
and preclinical research, will drive innovation forward,
and the clinical trial platform offers an efficient process
for rapid completion. The cooperation between Cancer
Core Europe and Cancer Prevention Europe will be
essential to expand the continuum to cover prevention,
making it imperative also to involve patient advocacy
groups like ECPC, and to work alongside policymakers
at the national and European levels, whereby the long-
evity of the mission will be ensured, making it manda-
tory to elicit effective social change. Overall, a
successful mission on cancer must benefit the advance-
ment of cancer research and of care for all.
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